Unlike other osteosarcoma cell lines (HOS, MG-63, and KHOS/NP), U2OS cells lack expression of the EGFR, the well-known target of gefitinib; therefore, GAK is a putative bona fide target of gefitinib in these cells. The gene discussed is EGFR; the disease is osteosarcoma.